Compare Elastic NV (ESTC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Repligen Corporation Common Stock — how do they compare? Elastic NV trades at $91.21 (market cap $9.67B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Elastic NV is more actively traded (1,592,425 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and Repligen Corporation Common Stock for 0 Days on average.
| ESTC | RGEN | |
|---|---|---|
Market Cap | $9.67B | $11.31B |
Volume | 1,592,425 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $99.91 | $194.57 |
52-Week Low | $43.30 | $102.87 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $8.80B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% today, but maintains strong technical momentum with a bullish moving average signal and recent earnings beats. The company shows impressive profitability metrics including 75.5% gross margins and 33.12% ROE, though current valuation appears elevated with a P/E of 26.3 and EV/EBITDA of 478.33. Recent product launches including AI-era metrics platform and serverless vector database demonstrate ongoing innovation in the competitive search and observability space.
ESTC presents a growth-oriented investment case with strong analyst support (64.7% buy ratings) and projected 29.6% upside to consensus target of $83.18. However, investors face risks from high valuation multiples, competitive pressures in enterprise software, and the company's transition to profitability after posting a $108M net loss in 2025 despite positive operational cash flow of $266M.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
